

Evaluation of Serum Osteopontin as a Predictor of Liver Fibrosis in Chronic Liver Disease

Thesis

*Submitted for Partial Fulfillment of Master Degree
in Clinical and Chemical Pathology*

By

Hoda Omar Ahmed

MB, B.Ch., Faculty of Medicine,
Ain Shams University

Supervised by

Professor/ Mona Mohamed Zaki

Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University

Professor/ Mona Mostafa Osman

Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University

Doctor/ Amira Ibrahim Hamed

Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University

*Faculty of Medicine
Ain Shams University*

2015

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة - آية ٣٢



Acknowledgements

First, and foremost, my deepest gratitude and thanks should be offered to **"ALLAH"**, the Most Kind and Most Merciful, for giving me the strength to complete this work.

I would like to express my sincere gratitude to **Professor/ Mona Mohamed Zaki**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her continuous support and guidance for me to present this work. It really has been an honor to work under her generous supervision.

I acknowledge with much gratitude to **Professor/ Mona Mostafa Osman**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her great supervision and unlimited help to provide all facilities to accomplish this work.

I acknowledge with much gratitude to **Doctor/ Amira Ibrahim Hamed**, Assistant Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her great efforts and time she has devoted to accomplish this work.

Last but not least, thanks to **my Parents** and **my Family** especially **my Husband** for helping me to finish this work.

✍ **Hoda Omar Ahmed**

Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	
List of Tables.....	
List of Figures	
Introduction	1
Aim of the Work.....	4
Review of Literature	
I- Chronic Liver Diseases.....	5
II-Osteopontin	55
III- Role of Osteopontin in Liver Diseases.....	73
Subjects and Methods	85
Results.....	101
Discussion	112
Summary	120
Recommendations	125
References	126
Arabic Summary	—

List of Abbreviations

Ab	: Antibody
AFP	: Alpha fetoprotein
Ag	: Antigen
AH	: Alcoholic hepatitis
AIH	: Autoimmune hepatitis
ALD	: Alcoholic liver disease
ALP	: Alkaline phosphatase
ALT	: Alanine transaminase
AMP	: Adenosine mono-phosphate
ANA	: Antinuclear antibodies
AST	: Aspartate transaminase
AUC	: Area under curve
BCS	: Budd–Chiari syndrome
CBC	: Complete blood count
CCI4	: Carbon tetrachloride
CF	: Cystic Fibrosis
CL	: Chemiluminescence immunoassay
CLD	: Chronic liver diseases
CT	: Computerize Tomography
ECM	: Extracellular matrix
EDHS	: Egyptian Demographic Health Survey
EGF	: Epidermal growth factor
EIAs	: Enzyme immunoassays
ELISPOT	: Enzyme-linked immunosorbent spot
ETA-1	: Early T-cell activation factor
EtOH	: Ethanol

List of Abbreviations *(Cont...)*

GAD	: Glutamic acid decarboxylase
GGT	: Gamma-glutamyltransferase
GRDS	: Glycine-arginine-aspartic acid-serine
GSD	: Glycogen storage diseases
HBcAg	: Hepatitis B core antigen
HBeAg	: Hepatitis B e antigen
HBV	: Hepatitis B virus
HCC	: Hepatocellular carcinoma
HCV	: Hepatitis C virus
HDV	: Hepatitis D virus
HE	: Hepatic encephalopathy
HRP	: Horseradish peroxidase
INR	: International normalization ratio
IRF	: Interferon regulatory factor-1
MELD	: Model for end-stage liver disease
MRI	: Magnetic resonance imaging
MS	: Multiple sclerosis
NAFLDs	: Non-alcoholic fatty liver diseases
NASH	: Non-alcoholic steatohepatitis
NKT	: Natural killer Tcells
OPN	: Osteopontin
PBC	: Primary biliary cirrhosis
PBMNC	: Peripheral blood mononuclear cells
PDGF	: Platelet derived growth factor
PT	: Prothrombin time

List of Abbreviations (*Cont...*)

RA	: Rheumatoid arthritis
ROC	: Receiver Operating Characteristic
RT-PCR	: Reverse transcriptase polymerase chain reaction
SGPT	: Serum glutamic pyruvate transaminase
SMA	: Smooth muscle actin
TGF	: Transforming growth factor
TNF-α	: Tumor necrosis factor alfa
VDREs	: Vitamin D responsive element
VEGF	: Vascular endothelial growth factor
WD	: Wilson disease
WT	: Wild type

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Tests Used in Diagnosing Chronic Liver Disease	45
Table (2):	Child-Pugh Classification of Chronic Liver Disease	47
Table (3):	Child-Pugh Score Interpretation	47
Table (4):	Staging of Liver Cirrhosis According to Different Classifications	50
Table (5):	METAVIR and Fibrotest	53
Table (6):	Descriptive Statistics of the Studied Parameters in the Three Studied Groups.	104
Table (7):	Comparative Statistics between Control Group and CLD Patients as regards OPN using Wilcoxon's Rank Sum Test.	105
Table (8):	Comparative Statistics between Control, Cirrhotic and Non-Cirrhotic Groups as Regards Osteopontin using Kruskal-Wallis Test.	105
Table (9):	Comparison of OPN among the Different Studied Groups using Wilcoxon's Rank-Sum Test.....	106
Table (10):	Statistical Comparison of Serum Osteopontin in Different Stages of Group Ia using Krushal-Walis Test.....	106
Table (11):	Statistical Comparison of OPN in the Different Stages of Patients' group Ia, using Wilcoxon's Rank-Sum Test.....	107

List of Tables (Cont.)

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (12):	Statistical Comparison of Serum Osteopontin between the Different Child-Pugh Stages of GroupIb, using Krushal-Wallis Test.....	107
Table (13):	Comparison of OPN in the Different Child Pugh Stages of GroupI b, using Wilcoxon's Rank-Sum Test.....	108
Table (14):	Correlation Analysis between OPN and Albumin, Bilirubin and INR in GroupIb using Spearman's Rank Correlation Coefficient.....	108
Table (15):	Diagnostic Performance of OPN in GroupIa Versus GroupII.	109
Table (16):	Diagnostic Performance of OPN in GroupIb versus GroupIa.	110
Table (17):	Diagnostic Performance of OPN in Mild Fibrosis Group versus Moderate and Severe Fibrosis Groups.....	111

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Structure of hepatitis C virus.....	9
Figure (2):	Levels of HBV markers in the blood	39
Figure (3):	Osteopontin gene structure.....	58
Figure (4):	Osteopontine receptors.This figure has been constructed from the following references.....	63
Figure (5):	Immunologic functions of OPN	66
Figure (6):	(ROC) curve analysis showing the diagnostic performance of OPN in Group Ia (non-cirrhotic) versus Group II (control).	109
Figure (7):	(ROC) curve analysis showing the diagnostic performance of OPN in Group Ib (cirrhotic) versus Group Ia (non-cirrhotic).	110
Figure (8):	(ROC) curve analysis showing the diagnostic performance of OPN in mild fibrosis group versus moderate and severe fibrosis groups.....	111

Introduction

Liver cirrhosis, the end stage of chronic liver diseases (CLD), is a major cause of mortality worldwide, where it accounts for approximately 850,000 death per year. Moreover, The disease is commonly complicated by the development of hepatocellular carcinoma (HCC), which is the fifth most common cancer in the world and the third most common cause of cancer related death among oncological patients (*Zhao et al., 2008*).

Hepatitis C virus (HCV) infection, the most common cause of CLD, is estimated to affect 170 million individuals worldwide. The published Egyptian Demographic Health Survey (EDHS) in 2009 estimated an overall anti-HCV antibody prevalence of 14.7%.The number of Egyptians estimated to be chronically infected was 9.8% (*Millera and Abu-Raddad, 2010*).

Although the majority (50-80%) of HCV-infected patients develops chronic infection, the disease progression is quite variable, where only about 15% of those chronically infected will eventually progress to cirrhosis after a median of 20–30 years post infection. Thus, identification of patients with accelerated fibrogenesis is of tremendous importance because early treatment can prevent development of cirrhosis and HCC (*Ghany et al., 2009*).

Several studies have observed that intrahepatic inflammation, especially lobular and/or peri-portal, is one of the most important determinants of fibrosis progression. The inflammatory reaction, mediated by intrahepatic T-helper 1 (Th-1) cells, leads to activation of stellate cells with excess deposition of extracellular matrix proteins and promotes ongoing tissue damage and fibrogenesis (*Wathmus et al., 2010*).

Liver biopsy is still the standard and most commonly used procedure in the assessment of liver fibrosis. However, it is an invasive method associated with patient discomfort and in rare cases with serious complications (*El-Shabrawi and Isa, 2011*). These limitations of the procedure have prompted a search for non-invasive markers of hepatic fibrosis. Non-invasive procedures such as transient elastography (FibroScan) and serum biomarkers (particularly Fibrometre, Fibrotest, Hepascore and APRI) have been developed in order to avoid biopsy, however, none of the currently available indices has sufficient accuracy to replace liver biopsy in the assessment of hepatic histology in patients with chronic HCV infection (*Degos et al., 2010*). The primary limitation of these indices is their inability to identify patients with intermediate stages of fibrosis (*Zeremski et al., 2009*).

Osteopontin (OPN) is a phosphorylated acid glycoprotein, secreted by multiple cell types including bone, kidney, epithelial

cells and activated immune cells. It is a Th-1 cytokine which acts as multi-functioning factor in cell adhesion and migration, immune and inflammatory response, vascular remodeling and apoptosis. OPN also induces extracellular matrix deposition by binding to type I collagen and fibronectin, contributing to tissue fibrotic process (*Suzuki et al., 2005*).

Recent studies have shown that OPN is expressed in activated Kupffer cells (hepatic macrophage) and stellate cells in experimentally liver necrosis. Moreover, elevated OPN levels were found in patients with early stages of HCC and were associated with poorer prognosis (*Sun et al., 2009*). These data suggest that OPN is correlated with the progression of liver disease, and hence it might be used as a marker of liver fibrosis and cirrhosis.

Aim of the Work

The aim of this thesis is to study the clinical utility of osteopontin serum level as a marker for prediction of degree of fibrosis in HCV related chronic liver diseases and to correlate its levels with the results of liver biopsy in patients with no evidence of hepatic cirrhosis or Child-Pugh classification in cirrhotic patients.

I- Chronic Liver Diseases

A. Definition:

Chronic liver diseases (CLDs) are characterized by progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis. Clinically it is defined as any hepatitis lasting for 6 months or longer (*Goldberg, 2009*).

B. Epidemiology:

Cirrhosis affects hundreds of millions of patients worldwide. The overall burden of liver disease in the United States, the vast majority of which is due to chronic disease with fibrosis, exacting an increasing economic and social cost (*Kim et al., 2002*).

Indeed, in the US cirrhosis is the most common non-neoplastic cause of death among hepatobiliary and gastrointestinal diseases, accounting for approximately 30,000 deaths per year. In addition, 10,000 deaths are due to liver cancer, the majority of which arise in cirrhotic livers, consistent with a steadily rising mortality rate from hepatic cancer. Notably, hepatocellular carcinoma is the most rapidly increasing neoplasm in the US and Western Europe (*Lefton et al., 2009*).